Table 4

 Hepatoprotective agents in the treatment of non-alcoholic fatty liver disease

AuthorInterventionNumberStudy typeComparisonDuration (months)ALTHistology
SteatosisInflammationFibrosis
“No change” if no statistically significant change reported. *Assessed by ultrasound; †fibrosis score improved compared with baseline but not in comparison with placebo at end of treatment.
Laurin82UDCA24Pilot trialBaseline12ImprovedImprovedNo changeNo change
Kiyici81UCDA17Pilot trialBaseline6ImprovedNANANA
Vajro95UCDA31Open label, randomisedDiet6No differenceNANANA
Lindor83UDCA166Blinded RCTPlacebo24No differenceNo differenceNo differenceNo difference
Abdelmalek79Betaine10Pilot trialBaseline12ImprovedImprovedNo differenceImproved
Merat75Probucol17Pilot trialBaseline6ImprovedNANANA
Merat76Probucol30Blinded RCTPlacebo6ImprovedNANANA
Adams78Pentoxifylline20Pilot trialBaseline12ImprovedNANANA
Satapathy77Pentoxifylline18Pilot trialBaseline6ImprovedNANANA
Loguercio86VSL no 322Pilot trialBaseline3ImprovedNANANA
Yokohama80Losartan7Pilot trialBaseline11ImprovedNo changeNo changeNo change
Hasegawa96Vitamin E22Pilot trialBaseline12ImprovedNo changeNo changeNo change
Kugelmas71Vitamin E + diet and exercise16Open label, randomisedDiet and exercise3No differenceNANANA
Vajro72Vitamin E28Blinded RCTPlacebo5No differenceNo difference*NANA
Harrison73Vitamin E + C45Blinded RCTPlacebo6No differenceNANo differenceNo difference†
Lavine97Vitamin E11Pilot trialBaseline5ImprovedNANANA